NEW YORK, NY / ACCESSWIRE / January 28, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors and Officers of Match Group, Inc. ("Match.com" or the "Company") (NasdaqGS:MTCH) for possible breaches of fiduciary duty.

Click here for more information: https://www.monteverdelaw.com/case/match-group-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

Monteverde & Associates PC is a national class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.

If you own common stock in Match Group, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

CONTACT:

Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE: Monteverde & Associates PC

ReleaseID: 574404

NORTH YORK, ON / ACCESSWIRE / January 28, 2020 / ZTEST Electronics Inc. ("ZTEST" or the "Company") (CSE:ZTE) wishes to announce that it will make an application to extend the exercise date of 312,500 warrants currently exercisable until January 31, 2020 at $1.10 per share, issued pursuant to the private placement financing which closed on January 30, 2018, for a further year until January 31, 2021 and to reduce the exercise price of the warrants to $0.40 per share.

The extension and re-pricing are subject to Canadian Securities Exchange ("CSE") approval and the consent of all warrant holders to the re-pricing of the warrants. In the event that, following approval of the amendment to the warrants, the closing price of the common shares of ZTEST on the CSE is at least $0.40 for ten (10) consecutive trading days (the last day being the "Tenth Trading Day"), the Company will issue a press release and file a Form 13 announcing that the expiry date of the warrants will be accelerated to thirty (30) days commencing seven (7) days after the Tenth Trading Day.

About ZTEST Electronics Inc.

ZTEST Electronics Inc., through its wholly owned subsidiary Permatech Electronics Corp. ("Permatech"), offers Electronic Manufacturing Services (EMS) to a wide range of customers. Permatech's offering includes Materials Management, Printed Circuit Board (PCB) Assembly, Testing and Design services. Permatech operates from a 20,000 square foot, ISO 9001:2015 certified facility in North York, Ontario, Canada. The company serves customers in the Medical, Power, Computer, Telecommunications, Wireless, Industrial and Consumer Electronics markets requiring high quality, quick-turnaround, small and medium size production runs. ZTEST also holds a 25.29% equity interest in Conversance Inc. ("Conversance").

About Conversance Inc.

Conversance, a Waterloo Ont. based private company founded by Mr. Joseph Chen, is focused on developing and marketing proprietary artificial intelligence supported distributed ledger technologies. Mr. Chen is an electrical engineer with a strong background in radio frequency, digital signal processing, VLSI (very-large-scale integration), complex systems, chemistry and physics. Mr. Chen joined Research In Motion (now BlackBerry) in 1999, becoming a senior member of the office of the chief technology officer ("CTO"), where he was instrumental in many of Blackberry's key telephony innovations and patents. While at BlackBerry, the office of the CTO first began looking into blockchain in 2008. Since leaving Blackberry in 2012, Mr. Chen has focused much of his personal research on the state of the art in machine learning, cryptography and quantum computing, and their implications and applications in digitizing and automating finance, and the protection of personal information and trust in a digital world.

For more information contact:

Steve Smith, CEO
(604) 837-3751
email: stevesmith15@shaw.ca

The CSE has neither approved nor disapproved the contents of this press release. The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: ZTEST Electronics Inc.

ReleaseID: 574403

VANCOUVER, BC / ACCESSWIRE / January 28, 2020 / Codebase Ventures Inc. ("Codebase" or the "Company") (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) announces it has completed a second closing of a non-brokered private placement. The Company issued 15,405,953 units at a price of $0.021 per unit, for gross proceeds of $323,525. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing. Securities issued pursuant to this financing are subject to trading restrictions until May 29, 2020.

The Company paid finders fees to qualified finders of $20,202 and issued 962,000 broker warrants, which are on the same terms as the warrants forming part of the units. Net proceeds from the private placement will be used for general working capital and to fund future investments.

About Codebase Ventures Inc.

Codebase Ventures Inc. is a small, hands-on team of financial and technology experts who invest early in great ideas. We operate from the understanding that technology is always evolving, bringing early opportunities for strategic investments that can deliver the exponential returns to our shareholders. We seek out and empower the innovators who are building tomorrow's standards with platforms and protocols, not just products. We invest early, support those founders, take their ideas to market and work tirelessly to help them realize their vision.

For further information, please contact:

Brian Keane, Director
Investor Relations
Telephone: 1 (778) 806-5150
E-mail: IR@codebase.ventures

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

SOURCE: Codebase Ventures Inc.

ReleaseID: 574402

NEW YORK, NY / ACCESSWIRE / January 28, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Geron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On September 27, 2018, Geron issued a press release disclosing disappointing results in the Company's IMbark study of imetelstat, its intended bone marrow cancer treatment. Specifically, Geron disclosed that patients in the IMbark study had shown only 10% spleen volume reduction and 32% TSS reduction, both of which metrics fell well short of the study's primary endpoints required for success. Concurrently, Geron disclosed the termination of its partnership with Janssen Biotech Inc. for the development of Imetelstat.

On this news, Geron's stock price fell $3.92 per share, or 62.92%, to close at $2.31 per share on September 27, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 574400

MURFREESBORO, TN / ACCESSWIRE / January 28, 2020 / National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the fourth quarter ended December 31, 2019. NHI plans to issue its earnings release before the market opens on Wednesday, February 19, 2020, and will host a conference call that day at 12 p.m. Eastern Time to discuss the results. The number to call for this interactive teleconference is (800) 582-1443, with the confirmation number 21950888.

The live broadcast of the conference call will be available online at www.nhireit.com and at https://www.webcaster4.com/Webcast/Page/633/32769 on Wednesday, February 19, 2020, at 12 p.m. Eastern Time. The online replay will be available shortly after the call and remain available for approximately 90 days.

About NHI

Incorporated in 1991, National Health Investors, Inc. (NYSE:NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI's portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals. For more information, visit www.nhireit.com.

Contact: Dana Hambly

Director, Investor Relations

Phone: (615) 890-9100

SOURCE: National Health Investors via EQS Newswire

ReleaseID: 574389

LOS ANGELES, CA / ACCESSWIRE / January 28, 2020 / MjLink.com Inc. a wholly owned subsidiary of Social Life Network, Inc. (OTCQB:WDLF), is pleased to announce Emerald Bioscience, Inc. (EMBI) as a Featured Presenter at their MjMicro Virtual Investor Conference hosted by MjInvest on Wednesday, January 29th at 1:00pm ET.

The MjMicro Virtual Investor Conference, hosted by MjInvest.com, provides a platform for both public and private cannabis companies to pitch and present their stories to investors through an online virtual conference, while providing a unique opportunity for private and institutional investors access and deal-flow to the best-in-class cannabis companies in the world. The MjInvest digital platform also allows companies and investors the ability to communicate after the conference concludes through chat features and direct messaging capabilities.

During the virtual conference, Dr. Brian Murphy, CEO of Emerald Bioscience, will host a featured presentation to update investors and analysts.

Emerald Bioscience (EMBI) is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.

CLICK HERE to add the Emerald Health online presentation to your calendar.

To access the Emerald Bioscience Virtual Presentation through the MjInvest Platform, please click this link on Wednesday, January 29th, 2020 at 10:00am PST / 1:00pm EST. https://www.mjinvest.com/emerald-health-therapeutics-presentation

About MjLink.com, Inc.

MjLink.com Inc. a wholly owned subsidiary of Social Life Network, Inc. and is a cloud-based cannabis social network and digital media company based in Denver, Colorado. MjLink operates as a multinational cannabis technology and digital media organization with four industry specific social networks: WeedLife.com, a consumer-to-consumer social network, MjLink.com, a business-to-business social network, HempTalk.com, a business-to-consumer social network, and MjInvest.com, a cannabis industry investor network that produces the MjMicro Capital Conference.

For more information about Social Life Network, visit www.SocialNetwork.ai

Disclaimer

This news release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company's analysis of opportunities in the acquisition and development of various project interests and certain other matters. No information in this press release should be construed as any indication whatsoever of the Company's or MjLink's future financial results, revenues or stock price. These statements are made under the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.

CONTACT:

Investor Relations
IR@Social-Life-Network.com
855-933-3277

SOURCE: Social Life Network, Inc.

ReleaseID: 574397

LOS ANGELES, CA / ACCESSWIRE / January 28, 2020 /  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grand Canyon Education, Inc. ("Grand Canyon" or "the Company") (NASDAQ:LOPE) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Grand Canyon is the focus of a report issued by Citron Research on January 28, 2020, entitled, "GCE, the Educational Enron." The report alleges that the Company utilized a "captive, non-reporting subsidiary to hide its liabilities … and artificially inflated the [company's] stock price." Based on this news, shares of Grand Canyon dropped sharply in intraday trading.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 574396

NEW YORK, NY / ACCESSWIRE / January 28, 2020 / There is so much talk about cannabidiol oil or CBD these days. You can hardly open up your email without seeing adverts and articles about the healing properties of CBD oil. But what is all the fuss about? How can oil linked to cannabis be good for you?

What is CBD oil?

Although CBD oil is from the same plant that gives us marijuana, CBD oil is different. It has had the chemical that causes the "high" removed from it. The chemical, known as THC, is controversial because some people say CBD doesn't work as well when it isn't combined with THC. However, there have been many studies on CBD without THC that show CBD oil can be helpful in several conditions.

In the US, CBD with less than 0.3% THC is legal. 0.3% is not enough to make a person "high".

Can CBD oil help you?

CBD oil may help with anxiety, depression, inflammation, insomnia, pain relief and more. This means for people affected by these illnesses, they can reduce their symptoms. This can make a huge difference, improving the lives of sufferers.

There is a study that has been done on the effects of CBD oil on depression and social anxiety, and it shows the cannabidiol have a positive effect on the serotonin receptors, which means they help people who have depression.

You can read more about our top 5 CBD oils here: https://topcbdoils.net/best-cbd-oil/

Can You Buy CBD Oil Safely?

What to look for:

If you are considering CBD oil for whatever reason, there could be a concern about buying the right type of oil. There are things to look out for that will help you make the best decision about CBD oil.

One of the first things to do is to look for a reputable website. This will be one with lots of information about CBD oil. It should be very clear about how they extract the CBD oil – CO2 is the best way.

When marijuana is treated with CO2, the temperature is reduced to very low, using specific equipment for this purpose. This method means the CBD oil contains higher quality cannabinoids. (Cannabinoids are chemicals within the marijuana that are helpful to the human body.)

Some people go to video websites to find out how to make CBD oil at home, however, this is not a good way to get the oil. You don't know where the cannabis is from, whether it's organic or not. It isn't a reliable way to get CBD oil.

It's important to remember that extracting cannabidiol oil or CBD is a chemical process, not a cooking process. It takes a scientist to achieve extraction in an accurate way. The scientist measures the levels of the cannabidiols in the CBD oil. This is how the website gets the information it gives you.

A reliable website must be very clear about the batch number. This is because the batch number contains information about the chemicals included in the oil. A responsible seller will include this information on their website.

It is best to have oil extracted right from the buds rather than other parts of the plant because the buds are a good source of oil.

Oil should be extracted from organically grown plants. Organic plants don't have toxic chemicals in them, so these are the best source of CBD oil.

So look for:

The buds of the plants used for extraction

Extraction methods using CO2

Organic plants used

Batch labels on every bottle produced

Full-spectrum oil – uses all the healthy cannabidiols from the plant

THC of less than 0.2% or 0.3% in the US

If a website sells CBD oils that tick all these boxes, then you are definitely on the right path. These all show legal, healthy and responsibly sourced CBD oil.

Then the best thing to do is check the reviews. Look for websites with plenty of reviews. The more reviews, the more accurate the ratings become. Look for people who suffer from the same issues as you – perhaps you are not sleeping well, and you have heard CBD oil helps with sleep. Then look for reviewers who mention either the quality or quantity of sleep on CBD oil.

As another example, if you are an anxious person, look for reviews that mention anxiety symptoms. Lots of websites make different formulas of CBD oil. Each one matches different issues. Make sure the type of CBD oil you choose matches the issues you are facing.

Always look for reviews that mention they are from verified buyers. Organizations buy reviews sometimes, but if the reviews mention someone by name and say they are a verified buyer, then they are much more likely to be genuine.

While there are no guarantees, such positive reviews mean that more and more people are finding CBD oil an effective way to control pain and other health issues. What could CBD oil do for you? The sooner you give it a try the sooner you'll know!

CONTACT:

Tim McComsey
Strategic Data Science
New York, New York
(770) 239-7752
info@sds.consulting

SOURCE: Strategic Data Sciences

ReleaseID: 574392

VANCOUVER, BC / ACCESSWIRE / January 28, 2020 / GGL Resources Corp. (TSXV:GGL) ("GGL" or the "Company") announces the resignation of Director Nick DeMare. Mr. DeMare has been a longstanding director of the Company.

The Board would like to thank Mr. DeMare for his many years of dedicated service to the Company.

About GGL Resources Corp.

GGL is a seasoned Canadian-based junior exploration company focused on diamond exploration in Canada's north with its priority, drill ready Stein project in Nunavut which has the potential to deliver a new diamond district. The Company also has several evolving projects in the Lac de Gras diamond district in the Northwest Territories. Lac de Gras is home to Canada's first two diamond mines, the world class Diavik and Ekati mines discovered in the 1990's. In addition to GGL's key focus of diamond exploration, it holds diamond Royalties on mineral leases in close proximity to the De Beers/Mountain Province Gahcho Kué diamond mine in the Northwest Territories. The Company also holds several encouraging base metal and gold projects in British Columbia and the Northwest Territories including the McConnell copper-gold porphyry and shear hosted gold project located 16 kilometers southeast of the Kemess Mine.

ON BEHALF OF THE BOARD

"David Kelsch"

David Kelsch
President, Chief Operating Officer and Director

For further information concerning GGL Resources Corp. or its various exploration projects please visit our website at www.gglresourcescorp.com or contact:

Investor Inquiries

Richard Drechsler
Corporate Communications
Tel: (604)687-2522, extension 262
NA Toll-Free: (888) 688-2522
r.drechsler@gglresourcescorp.com

Corporate Information

Linda Knight
Corporate Secretary
Tel: (604)688-0546
info@gglresourcescorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward looking statements based on assumptions and judgments of management regarding future events or results that may prove to be inaccurate as a result of exploration and other risk factors beyond its control, and actual results may differ materially from the expected results.

SOURCE: GGL Resources Corp.

ReleaseID: 574368

EDISON, NJ / ACCESSWIRE / January 28, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion" or the "Company"), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced positive findings from an expanded study with human precision cut liver slices ("PCLS"). In this specialized experimental model using human liver tissue, Hepion's drug candidate, CRV431, prevented experimentally induced liver fibrosis to a greater extent than four other leading NASH drug candidates: obeticholic acid ("OCA", an FXR agonist), elafibranor (a PPARα/δ agonist), resmetirom (a THR-β agonist), and Aramchol (an SCD1 inhibitor). These results support the potential for CRV431 to exert potent antifibrotic activity in NASH.

The study was conducted by FibroFind, a spin-out contract research company from the Fibrosis Research Group at Newcastle University, Newcastle Upon Tyne, UK. Liver tissue was obtained from three separate human donors and exposed to TGF-β1 and PDGF-BB, which are potent biological inducers of inflammation and fibrosis. The study design and its findings were similar to a previous study conducted by Hepion and FibroFind in which CRV431 was tested on tissue from a single human donor. In a combined data analysis of all of four donor samples, CRV431 was the only one of the five drug candidates that, on average, completely prevented TGF-β1- and PDGF-BB-induced fibrosis. The comparator compounds in these studies were administered at equimolar or higher concentrations than CRV431. Furthermore, CRV431 was also able to diminish endogenous fibrotic activity in diseased liver samples from three of four donors in the absence of added TGF-β1 and PDGF-BB. In addition to the reductions in tissue fibrosis, as measured by Picrosirius Red staining, CRV431 decreased gene expression and secretion of several markers of inflammation and fibrosis, including IL-6, MCP-1, collagen 1α1, hyaluronic acid, and TIMP-1.

Dr. Jelena Mann, CEO of FibroFind commented, "We have spent years optimizing PCLS because we believe it is the most representative experimental model of what actually occurs in the human body and is therefore one of the most predictive for testing drug candidates. To date, we have evaluated dozens of investigational drugs from academia and industry, and CRV431 has been one of the most potent and consistent antifibrotic drug candidates that we've tested. Based on our findings, we believe that CRV431 shows strong potential for treating liver fibrosis."

"CRV431 offers a novel approach to the treatment of fibrosis caused by NASH and possibly other causes of liver injury," stated Dr. Robert Foster, CEO of Hepion Pharmaceuticals. "This is because CRV431 acts, in part, by directly targeting fibrotic scar formation by down-regulating an important regulator of collagen synthesis, cyclophilin B, thereby reducing collagen production. This contrasts with most other NASH drug candidates that target events such as dyslipidemia or diabetes that may lead to fibrosis. Combining the direct antifibrotic actions of CRV431 with the indirect actions of other drug candidates likely represents the best opportunity for rapidly and effectively decreasing liver fibrosis in NASH."

Hepion is developing CRV431 for NASH, fibrosis and other liver diseases. A Phase 1, single ascending dose study previously showed CRV431 to be safe and well tolerated in humans. Currently, CRV431 is being administered to humans in a 28-day multiple ascending dose study.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company's lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431's potent inhibition of cyclophilins, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend," among others. These forward-looking statements are based on Hepion Pharmaceuticals' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2018 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com

SOURCE: Hepion Pharmaceuticals, Inc.

ReleaseID: 574373